| EP2308879A1 (en) | 2004-04-02 | 2011-04-13 | OSI Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| WO2007002093A2 (en)* | 2005-06-21 | 2007-01-04 | Infinity Discovery, Inc. | Ansamycin formulations and methods of use thereof |
| AU2007254179B2 (en)* | 2006-05-18 | 2013-03-21 | Pharmacyclics Llc | Intracellular kinase inhibitors |
| KR101462693B1 (ko)* | 2006-08-16 | 2014-11-17 | 노파르티스 아게 | 고도 결정질 치료용 화합물의 고체 분산체 제조 방법 |
| PL2526934T4 (pl) | 2006-09-22 | 2016-09-30 | | Inhibitory kinazy tyrozynowej Brutona |
| WO2008054827A2 (en)* | 2006-11-03 | 2008-05-08 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| CA3143428A1 (en)* | 2007-03-28 | 2008-10-09 | Pharmacyclics Llc | 8-amino-3-substituted-imidazo[1,5-a]pyrazine and use thereof as inhibitors of bruton's tyrosine kinase |
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| WO2008128063A1 (en)* | 2007-04-12 | 2008-10-23 | Infinity Discovery, Inc. | Hydroquinone ansamycin formulations |
| US7989465B2 (en)* | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| TWI552752B (zh)* | 2007-10-19 | 2016-10-11 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| JP2011510018A (ja)* | 2008-01-18 | 2011-03-31 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 癌治療のためのイミダゾピラジノール誘導体 |
| EP2283020B8 (en)* | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituted imidazopyr-and imidazotri-azines |
| US20100101977A1 (en)* | 2008-06-05 | 2010-04-29 | United Comb & Novelty Corporation | Stackable Packaging For Lipped Containers |
| US8338439B2 (en)* | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| EP2307413B1 (en)* | 2008-07-15 | 2015-09-09 | F. Hoffmann-La Roche AG | Novel phenyl-imidazopyridines and pyridazines |
| EP3311818A3 (en)* | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| AU2013245503B2 (en)* | 2008-07-16 | 2015-09-24 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
| MY156789A (en)* | 2008-09-05 | 2016-03-31 | Celgene Avilomics Res Inc | Algorithm for designing irreversible inhibitors |
| US8778921B2 (en) | 2008-10-15 | 2014-07-15 | Infinity Pharmaceuticals, Inc. | Ansamycin hydroquinone compositions |
| WO2010043633A1 (en)* | 2008-10-15 | 2010-04-22 | Palau Pharma, S. A. | 2h-pyrazolo [4,3-d]pyrimidin-5-amine derivatives as h4 histamine receptor antagonists for the treatment of allergic, immunological and inflammatory diseases |
| US9095592B2 (en)* | 2008-11-07 | 2015-08-04 | The Research Foundation For The State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
| US8426428B2 (en)* | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| CN102405214A (zh) | 2009-04-20 | 2012-04-04 | Osi药物有限责任公司 | C-吡嗪-甲胺的制备 |
| JP5656976B2 (ja)* | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
| CN102482277B (zh) | 2009-05-05 | 2017-09-19 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
| JP2012526138A (ja)* | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 副腎皮質癌を治療するためのｏｓｉ−９０６の使用 |
| EP3461824B1 (en) | 2009-09-04 | 2021-08-25 | Biogen MA Inc. | Bruton's tyrosine kinase inhibitors |
| IN2012DN03112A (lt)* | 2009-09-11 | 2015-09-18 | Cylene Pharamaceuticals Inc | |
| JP5806670B2 (ja) | 2009-09-16 | 2015-11-10 | セルジーン アビロミクス リサーチ， インコーポレイテッド | プロテインキナーゼコンジュゲート及びインヒビター |
| US7965498B2 (en) | 2009-09-30 | 2011-06-21 | Apple Inc. | Cover glass to housing interface system |
| US7718662B1 (en)* | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| KR20130067487A (ko) | 2009-12-30 | 2013-06-25 | 아빌라 테라퓨틱스, 인크. | 단백질의 리간드-지정 공유 변형 |
| EP2545044A1 (en)* | 2010-03-08 | 2013-01-16 | ratiopharm GmbH | Dabigatran etexilate-containing pharmaceutical composition |
| US9371567B2 (en)* | 2010-04-19 | 2016-06-21 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of BTK inhibitors |
| EP3590938B1 (en) | 2010-05-31 | 2023-05-24 | ONO Pharmaceutical Co., Ltd. | Purinone derivative as btk kinase inhibitor |
| EP2575818A4 (en) | 2010-06-03 | 2013-11-06 | Pharmacyclics Inc | USE OF BRUTON TYROSINE KINASE INHIBITORS (BTK) |
| US20120053189A1 (en)* | 2010-06-28 | 2012-03-01 | Pharmacyclics, Inc. | Btk inhibitors for the treatment of immune mediated conditions |
| WO2012003544A1 (en) | 2010-07-09 | 2012-01-12 | The Walter And Eliza Hall Institute Of Medical Research | Protein kinase inhibitors and methods of treatment |
| RU2013109393A (ru) | 2010-08-10 | 2014-09-20 | Сэлджин Авиаломикс Ресеарч, Инк. | Безилатная соль ингибитора втк |
| MX2013001970A (es)* | 2010-08-20 | 2013-08-09 | Hutchison Medipharma Ltd | Compuestos de pirrolopirimidina y usos de los mismos. |
| WO2012061303A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
| CA2815858C (en) | 2010-11-01 | 2018-10-16 | Celgene Avilomics Research, Inc. | Heterocyclic compounds and uses thereof |
| JP5957003B2 (ja) | 2010-11-10 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | 変異体選択的ｅｇｆｒ阻害剤およびその使用 |
| WO2012114222A1 (en) | 2011-02-23 | 2012-08-30 | Pfizer Inc. | IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| WO2012158810A1 (en)* | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| JP6068451B2 (ja) | 2011-05-17 | 2017-01-25 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア | キナーゼ阻害剤 |
| PL2710005T3 (pl)* | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
| CA2840413A1 (en)* | 2011-06-28 | 2013-01-03 | Pharmacyclics, Inc. | Methods and compositions for inhibition of bone resorption |
| EP2726634B1 (en) | 2011-07-01 | 2017-02-22 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma |
| MX2014000338A (es) | 2011-07-08 | 2014-05-01 | Novartis Ag | Derivados de pirrolo-pirimidina novedoso. |
| BR112014000653A2 (pt)* | 2011-07-13 | 2017-02-14 | Pharmacyclics Inc | inibidores de tirosina quinase de bruton |
| EP2548877A1 (en)* | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| SMT202100729T1 (it) | 2011-07-19 | 2022-01-10 | Merck Sharp & Dohme | 4-imidazopiridazin-1-il-benzammidi e 4-imidazotriazin-1-ilbenzammidi come inibitori di btk |
| US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
| SG11201401625TA (en)* | 2011-10-19 | 2014-05-29 | Pharmacyclics Inc | Use of inhibitors of bruton's tyrosine kinase (btk) |
| TW201325593A (zh) | 2011-10-28 | 2013-07-01 | Celgene Avilomics Res Inc | 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法 |
| GB2496135B (en) | 2011-11-01 | 2015-03-18 | Valirx Plc | Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis |
| US8722676B2 (en)* | 2011-11-03 | 2014-05-13 | Genentech, Inc. | Bicyclic piperazine compounds |
| UA111756C2 (uk)* | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US9212381B2 (en)* | 2011-11-10 | 2015-12-15 | President And Fellows Of Harvard College | Methods and compositions for labeling polypeptides |
| AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
| CN103958513B (zh) | 2011-11-29 | 2015-12-23 | 小野药品工业株式会社 | 6-羟基嘌呤衍生物盐酸盐 |
| US8377946B1 (en)* | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| DK2802328T3 (en) | 2012-01-09 | 2018-06-14 | X Chem Inc | TRYPTOLIN DERIVATIVES WITH KINASE INHIBITIVE ACTIVITY AND APPLICATIONS THEREOF |
| CN104080789B (zh)* | 2012-01-31 | 2016-05-11 | 南京奥昭生物科技有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| TW201336847A (zh)* | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| TWI496783B (zh)* | 2012-02-23 | 2015-08-21 | Taiho Pharmaceutical Co Ltd | Quinolylpyrrolopyrimidine condensed cyclic compounds or salts thereof |
| CN103312670A (zh) | 2012-03-12 | 2013-09-18 | 西安西电捷通无线网络通信股份有限公司 | 一种认证方法及系统 |
| KR102081042B1 (ko) | 2012-03-15 | 2020-02-26 | 셀젠 카르 엘엘씨 | 상피 성장 인자 수용체 키나제 억제제의 고체 형태 |
| EP2825042B1 (en) | 2012-03-15 | 2018-08-01 | Celgene CAR LLC | Salts of an epidermal growth factor receptor kinase inhibitor |
| US9365566B2 (en) | 2012-03-27 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives |
| CN104203242B (zh) | 2012-04-04 | 2017-03-15 | 杭州德润玉成生物科技有限公司 | 取代的喹啉类作为布鲁顿酪氨酸激酶抑制剂 |
| WO2013154778A1 (en) | 2012-04-11 | 2013-10-17 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
| US9522917B2 (en) | 2012-04-11 | 2016-12-20 | Acerta Pharma B.V. | Bruton's tyrosine kinase inhibitors for hematopoietic mobilization |
| CN103374001B (zh)* | 2012-04-19 | 2015-10-28 | 山东轩竹医药科技有限公司 | 咪唑并三嗪类mTOR抑制剂 |
| CA2874211A1 (en)* | 2012-05-31 | 2013-12-05 | Pharmascience Inc. | Protein kinase inhibitors |
| US9296753B2 (en) | 2012-06-04 | 2016-03-29 | Pharmacyclics Llc | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
| AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| CN104487441B (zh)* | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
| WO2014004707A1 (en) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| EP3550031A1 (en) | 2012-07-24 | 2019-10-09 | Pharmacyclics, LLC | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| IN2015DN00598A (lt)* | 2012-07-30 | 2015-06-26 | Concert Pharmaceuticals Inc | |
| WO2014022569A1 (en)* | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
| JP6348492B2 (ja) | 2012-08-10 | 2018-06-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤としてのヘテロ芳香族化合物 |
| CN103121999A (zh)* | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
| EP2890691B1 (en) | 2012-08-31 | 2018-04-25 | Principia Biopharma Inc. | Benzimidazole derivatives as itk inhibitors |
| KR102203990B1 (ko) | 2012-09-10 | 2021-01-18 | 프린시피아 바이오파마, 인코퍼레이티드 | 키나제 저해제로서의 피라졸로피리미딘 화합물 |
| CH706997A1 (en) | 2012-09-20 | 2014-03-31 | Ferag Ag | Access control on operating modules of a control unit. |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CN111329989A (zh) | 2012-11-02 | 2020-06-26 | 药品循环有限责任公司 | Tec家族激酶抑制剂辅助疗法 |
| MD20150035A2 (ro) | 2012-11-02 | 2015-10-31 | Pfizer Inc. | Inhibitori de tirozinkinaza Bruton |
| MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
| JP6322204B2 (ja) | 2012-11-16 | 2018-05-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ジヒドロピラゾールのｇｐｒ４０モジュレーター |
| CN103848810A (zh)* | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| KR20150111918A (ko)* | 2012-12-21 | 2015-10-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트의 경점막 전달 |
| EP2948458B1 (en)* | 2013-01-23 | 2019-05-01 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| WO2014113942A1 (en)* | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| WO2014113932A1 (en)* | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| EP2953457B1 (en) | 2013-02-08 | 2020-04-08 | Celgene CAR LLC | Erk inhibitors and uses thereof |
| US20140357636A1 (en)* | 2013-02-21 | 2014-12-04 | Wayne Rothbaum | Treatment of Skeletal-Related Disorders |
| BR112015018222A2 (pt) | 2013-02-22 | 2017-07-18 | Taiho Pharmaceutical Co Ltd | método para produzir um composto tricíclico, e composto tricíclico que pode ser produzido pelo referido método de produção |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| US9610282B2 (en)* | 2013-03-12 | 2017-04-04 | Nbip, Llc | Compositions and methods for preventing infection of a wound and for advancing the healing process |
| CN103142601A (zh)* | 2013-03-13 | 2013-06-12 | 杭州雷索药业有限公司 | Pci-32765在制备抗血管生成类药物中的应用 |
| KR20210149232A (ko) | 2013-03-14 | 2021-12-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법 |
| WO2014151620A1 (en) | 2013-03-14 | 2014-09-25 | Boehringer Ingelheim International Gmbh | 5-thiazolecarboxamide dervatives and their use as btk inhibitors |
| JP2016512549A (ja)* | 2013-03-14 | 2016-04-28 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ |
| WO2014152114A1 (en) | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as btk inhibitors |
| JP6777398B2 (ja)* | 2013-03-15 | 2020-10-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 薬剤を調製するための方法と中間体 |
| US9156847B2 (en)* | 2013-03-15 | 2015-10-13 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
| KR20210091832A (ko) | 2013-03-15 | 2021-07-22 | 셀젠 카르 엘엘씨 | Mk2 억제제 및 이의 용도 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| WO2014168986A1 (en) | 2013-04-08 | 2014-10-16 | Brown Dennis M | Therapeutic benefit of suboptimally administered chemical compounds |
| MX369503B (es)* | 2013-04-08 | 2019-11-11 | Pharmacyclics Llc | Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas. |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| KR101793807B1 (ko) | 2013-04-25 | 2017-11-03 | 베이진 엘티디 | 단백질 키나제 억제제로서의 융합된 헤테로시클릭 화합물 |
| GB2513615A (en) | 2013-05-01 | 2014-11-05 | Cancer Rec Tech Ltd | Medical use |
| GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| EP2999702A4 (en)* | 2013-05-21 | 2017-01-11 | Jiangsu Medolution Ltd. | Substituted pyrazolopyrimidines as kinases inhibitors |
| WO2015002894A1 (en)* | 2013-07-02 | 2015-01-08 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| RU2016101548A (ru) | 2013-07-03 | 2017-08-08 | Ф. Хоффманн-Ля Рош Аг | Соединения амидов гетероарилпиридона и азапиридона |
| CN105764502A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群及其类似物及衍生物的治疗益处的组合方法 |
| EP3027192A4 (en) | 2013-08-02 | 2017-03-22 | Pharmacyclics, LLC | Methods for the treatment of solid tumors |
| EP2832358A1 (en) | 2013-08-02 | 2015-02-04 | Bionsil S.r.l. | Pharmaceutical kit for use in the treatment of colon and colorectal cancer |
| EP3033079B1 (en) | 2013-08-12 | 2018-10-31 | Pharmacyclics LLC | Methods for the treatment of her2 amplified cancer |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| BR112016005408B1 (pt) | 2013-09-13 | 2023-03-21 | Beigene Switzerland Gmbh | Anticorpos anti-pd1, f(ab) ou f(ab)2 e uso referido anticorpo para tratamento de cancer ou infecção viral |
| SI3052476T1 (sl) | 2013-09-30 | 2020-12-31 | Guangzhou Innocare Pharma Tech Co., Ltd. | Substituirani nikotinimidni inhibitorji BTK in njihova priprava in uporaba pri zdravljenju raka, vnetja in avtoimunske bolezni |
| JP2016531941A (ja)* | 2013-09-30 | 2016-10-13 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼの阻害剤 |
| EP3054954A4 (en)* | 2013-10-10 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma |
| WO2015057992A1 (en) | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
| CA2922044A1 (en)* | 2013-10-18 | 2015-05-14 | Medivation Technologies, Inc. | Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk) |
| AU2014337122B2 (en) | 2013-10-18 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| US20210317140A1 (en) | 2013-10-18 | 2021-10-14 | Medivation Technologies, Inc. | Heterocyclic Compounds and Methods of Use |
| CN105849099B (zh) | 2013-10-18 | 2020-01-17 | 达纳-法伯癌症研究所股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的多环抑制剂 |
| BR112016009200A8 (pt)* | 2013-10-25 | 2020-03-24 | Pharmacyclics Llc | uso de um inibidor de btk e um inibidor imune do ponto de verificação |
| TWI620565B (zh)* | 2013-10-25 | 2018-04-11 | 製藥公司 | 治療及預防移植物抗宿主病之方法 |
| US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
| WO2015071432A1 (en) | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
| US20150141438A1 (en)* | 2013-11-15 | 2015-05-21 | Pharmacyclics, Inc. | Methods for delaying or preventing the onset of type 1 diabetes |
| CN103626774B (zh)* | 2013-11-20 | 2015-11-04 | 苏州明锐医药科技有限公司 | 伊鲁替尼的制备方法 |
| CA2833867A1 (en)* | 2013-11-21 | 2015-05-21 | Pharmascience Inc. | Protein kinase inhibitors |
| CN103694241A (zh) | 2013-11-27 | 2014-04-02 | 苏州晶云药物科技有限公司 | Pci-32765的新晶型a及其制备方法 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| BR112016012158A2 (pt) | 2013-12-02 | 2017-09-26 | Pharmacyclics Llc | métodos de tratamento e prevenção da doença do enxerto contra o hospedeiro crônica dirigida a aloanticorpo |
| BR112016012794A2 (pt) | 2013-12-05 | 2017-08-08 | Acerta Pharma Bv | Combinação terapêutica de um inibidor de pi3k e um inibidor de btk |
| MD4649C1 (ro) | 2013-12-05 | 2020-04-30 | Pfizer Inc. | Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide |
| JP6275846B2 (ja) | 2013-12-05 | 2018-02-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 求電子性官能基を有するヘテロアリールピリドン及びアザ−ピリドン化合物 |
| US9908872B2 (en)* | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US9834554B2 (en) | 2013-12-20 | 2017-12-05 | Merck Sharp & Dohme Corp. | BTK inhibitors |
| US9637486B2 (en) | 2013-12-20 | 2017-05-02 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| US9828364B2 (en) | 2014-01-29 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as BTK inhibitors |
| CN106008514A (zh)* | 2014-01-29 | 2016-10-12 | 苏州晶云药物科技有限公司 | 依鲁替尼的新晶型及其制备方法 |
| AU2015225745B2 (en)* | 2014-02-03 | 2017-04-20 | Cadila Healthcare Limited | Heterocyclic compounds |
| BR112016018948B1 (pt) | 2014-02-21 | 2023-01-17 | Principia Biopharma Inc | Uso de composto ou sal farmaceuticamente aceitável, ácido sulfônico ou sal de ácido carboxílico de composto, forma amorfa de sal farmaceuticamente aceitável de composto, composição farmacêutica e respectivo uso |
| CA2940666C (en) | 2014-02-28 | 2022-08-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| JP2017509336A (ja) | 2014-03-20 | 2017-04-06 | ファーマサイクリックス エルエルシー | ホスホリパーゼｃガンマ２及び耐性に関連した変異 |
| GB201404987D0 (en)* | 2014-03-20 | 2014-05-07 | Redx Pharma Ltd | Compounds |
| WO2015146159A1 (en) | 2014-03-25 | 2015-10-01 | Ono Pharmaceutical Co., Ltd. | Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma |
| US9884869B2 (en)* | 2014-03-27 | 2018-02-06 | Perrigo Api Ltd. | Ibrutinib solid forms and production process therefor |
| WO2015151006A1 (en)* | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
| WO2015181633A2 (en) | 2014-04-11 | 2015-12-03 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
| WO2015185998A2 (en) | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
| CN105017256A (zh)* | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN105085474B (zh)* | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| CN105085529A (zh)* | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
| CN104086551B (zh)* | 2014-06-06 | 2016-09-21 | 人福医药集团股份公司 | 化合物及其制备方法和用途 |
| GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
| WO2015193740A2 (en) | 2014-06-17 | 2015-12-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor |
| CN104945404B (zh)* | 2014-06-25 | 2018-09-14 | 广东东阳光药业有限公司 | 一种n-丙烯羰基哌啶衍生物的制备方法 |
| WO2016004305A2 (en)* | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| CN105294571B (zh)* | 2014-07-03 | 2019-04-23 | 浙江九洲药业股份有限公司 | 一种依鲁替尼中间体及其制备方法和用途 |
| KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| ES2706745T3 (es)* | 2014-07-07 | 2019-04-01 | Jiangsu Hengrui Medicine Co | Compuestos de aminopiridazinona como inhibidores de proteína cinasa |
| WO2016008411A1 (en)* | 2014-07-18 | 2016-01-21 | Beigene, Ltd. | 5-amino-4-carbamoyl-pyrazole compounds as selective and irreversible t790m over wt-egfr kinase inhibitors and use thereof |
| WO2016019237A2 (en)* | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| WO2016019233A1 (en)* | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| EP3193877A4 (en) | 2014-08-07 | 2018-04-04 | Pharmacyclics LLC | Novel formulations of a bruton's tyrosine kinase inhibitor |
| WO2016020901A1 (en) | 2014-08-07 | 2016-02-11 | Acerta Pharma B.V. | Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate |
| CN105461720B (zh)* | 2014-08-08 | 2019-08-06 | 南京圣和药业股份有限公司 | 吗啉类酪氨酸激酶抑制剂 |
| JP2017523207A (ja) | 2014-08-08 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用 |
| WO2016024227A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
| DK3179992T3 (da) | 2014-08-11 | 2022-07-11 | Acerta Pharma Bv | Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor |
| SI3179991T1 (sl) | 2014-08-11 | 2022-04-29 | Acerta Pharma B.V. | Terapevtske kombinacije zaviralca BTK in zaviralca BCL-2 |
| WO2016024232A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
| WO2016023082A1 (en) | 2014-08-12 | 2016-02-18 | Monash University | Lymph directing prodrugs |
| WO2016025561A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Forms and compositions of an erk inhibitor |
| WO2016025720A1 (en) | 2014-08-14 | 2016-02-18 | Assia Chemical Industries Ltd. | Solid state forms of ibrutinib |
| WO2016050921A1 (en) | 2014-10-02 | 2016-04-07 | F. Hoffmann-La Roche Ag | Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk) |
| US10112957B2 (en) | 2014-10-22 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| LT3461821T (lt) | 2014-10-24 | 2020-08-10 | Bristol-Myers Squibb Company | Indolo karboksamido junginiai, naudotini kaip kinazės inhibitoriai |
| WO2016066490A1 (en) | 2014-10-27 | 2016-05-06 | F. Hoffmann-La Roche Ag | Process for making tricyclic lactam compounds |
| SMT202100301T1 (it) | 2014-10-29 | 2021-07-12 | Bicyclerd Ltd | Ligandi peptidici biciclici specifici per mt1-mmp |
| WO2016066673A1 (en)* | 2014-10-30 | 2016-05-06 | Sandoz Ag | Synthesis of substituted 1h-pyrazolo[3,4-d]pyrimidines |
| WO2016079693A1 (en)* | 2014-11-19 | 2016-05-26 | Sun Pharmaceutical Industries Limited | A process for the preparation of ibrutinib |
| WO2016079216A1 (en) | 2014-11-20 | 2016-05-26 | Sandoz Ag | Physical forms of ibrutinib, a bruton's kinase inhibitor |
| CN104447761A (zh)* | 2014-11-27 | 2015-03-25 | 广东东阳光药业有限公司 | 一种吡唑衍生物的制备方法 |
| AR102871A1 (es) | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
| WO2016088074A1 (en)* | 2014-12-03 | 2016-06-09 | Dr. Reddy’S Laboratories Limited | Process for the preparation of amorphous ibrutinib |
| WO2016087994A1 (en) | 2014-12-05 | 2016-06-09 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
| CN104478884A (zh)* | 2014-12-05 | 2015-04-01 | 广东东阳光药业有限公司 | 一种中间体的制备方法 |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| CN117865872A (zh) | 2014-12-18 | 2024-04-12 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| EA036269B1 (ru) | 2014-12-18 | 2020-10-21 | Принсипиа Биофарма Инк. | Лечение пузырчатки |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2016106624A1 (en)* | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
| WO2016106652A1 (en)* | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Biarylether imidazopyrazine btk inhibitors |
| WO2016106628A1 (en)* | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| WO2016106629A1 (en)* | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| CN105820168B (zh)* | 2015-01-09 | 2018-12-04 | 上海医药工业研究院 | 一种依鲁替尼中间体的制备方法 |
| MA41350A (fr)* | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| WO2016115869A1 (zh) | 2015-01-21 | 2016-07-28 | 中国科学院合肥物质科学研究院 | Flt3激酶的新型抑制剂及其用途 |
| WO2016123504A1 (en)* | 2015-01-30 | 2016-08-04 | Pharmacyclics Llc | Btk inhibitor combinations and multidrug-resistance |
| CZ201584A3 (cs) | 2015-02-09 | 2016-08-17 | Zentiva, K.S. | Sůl Ibrutinib sulfátu |
| CN107207519B (zh)* | 2015-02-12 | 2019-11-08 | 正大天晴药业集团股份有限公司 | 伊布替尼的制备方法 |
| WO2016132383A1 (en) | 2015-02-18 | 2016-08-25 | Mylan Laboratories Limited | Process for the preparation of ibrutinib |
| EP3262049B1 (en) | 2015-02-27 | 2022-07-20 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| IL315294A (en)* | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| US10045990B2 (en) | 2015-03-04 | 2018-08-14 | Arizona Board Of Regents On Behalf Of Arizona State University | ERBB4 inhibitors and methods of use thereof |
| CN106146508A (zh)* | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| MA41827A (fr) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| MA41828A (fr) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton |
| WO2016161248A1 (en)* | 2015-04-02 | 2016-10-06 | Tolero Pharmaceuticals, Inc. | Targeting pim kinases in combination with btk inhibition |
| JP6705833B2 (ja) | 2015-04-02 | 2020-06-03 | ラティオファルム ゲー・エム・ベー・ハー | イブルチニブとカルボン酸との共結晶 |
| CN106146511A (zh)* | 2015-04-03 | 2016-11-23 | 安润医药科技（苏州）有限公司 | 吡唑并嘧啶衍生物、制备方法、药物组合物及用途 |
| CN105906621A (zh)* | 2015-04-06 | 2016-08-31 | 四川百利药业有限责任公司 | 用作fgfr抑制剂的乙醇类化合物 |
| FI3892302T3 (fi) | 2015-04-06 | 2023-11-03 | Janssen Pharmaceutica Nv | Ibrutinibia sisältäviä koostumuksia |
| PT3280729T (pt) | 2015-04-08 | 2022-08-01 | Novartis Ag | Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19 |
| ES2955554T3 (es) | 2015-04-09 | 2023-12-04 | Ono Pharmaceutical Co | Proceso para producir un derivado de purinona |
| CN106146512B (zh)* | 2015-04-09 | 2018-07-17 | 北京睿创康泰医药研究院有限公司 | 依鲁替尼的制备方法 |
| KR20170134462A (ko)* | 2015-04-13 | 2017-12-06 | 다이이찌 산쿄 가부시키가이샤 | Mdm2 저해제와 btk 저해제의 병용 치료법 |
| CN106146482B (zh)* | 2015-04-14 | 2020-06-23 | 宁波文达医药科技有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
| WO2016170545A1 (en)* | 2015-04-22 | 2016-10-27 | Msn Laboratories Private Limited | Process for the preparation of 1-[(3r)-3-[4-amino-3-(4-phenoxyphenvl)-1h- pvrazolo[3,4-d]pyriniidin-1-y1]-1-piperidinvl]-2-propen-1-one and its polymorphs thereof |
| EP3195865A1 (de) | 2016-01-25 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Kombinationen von irak4 inhibitoren und btk inhibitoren |
| US20180289685A1 (en) | 2015-04-30 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| CN107660151B (zh) | 2015-05-26 | 2022-03-11 | 莫佛塞斯公司 | 抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途 |
| JP6646072B2 (ja)* | 2015-06-03 | 2020-02-14 | プリンシピア バイオファーマ インコーポレイテッド | チロシンキナーゼ阻害剤 |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| US9394312B1 (en)* | 2015-06-14 | 2016-07-19 | Mark Quang Nguyen | Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use |
| RU2719477C2 (ru)* | 2015-06-22 | 2020-04-17 | Оно Фармасьютикал Ко., Лтд. | Соединение, ингибирующее brk |
| TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
| CZ2015442A3 (cs)* | 2015-06-26 | 2017-01-04 | Zentiva, K.S. | Ibrutinib hemisulfát |
| WO2016207172A1 (en)* | 2015-06-26 | 2016-12-29 | Sandoz Gmbh | Preparation of pure amorphous ibrutinib |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| MX2020014163A (es) | 2015-07-02 | 2022-09-29 | Acerta Pharma Bv | Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida. |
| ES2764497T3 (es) | 2015-07-02 | 2020-06-03 | Hoffmann La Roche | Compuestos de benzoxazepina oxazolidinona y procedimientos de uso |
| EP3317283B1 (en) | 2015-07-02 | 2019-04-03 | H. Hoffnabb-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| ITUB20152576A1 (it)* | 2015-07-29 | 2017-01-29 | Laboratorio Chimico Int S P A | Procedimento per la preparazione di ibrutinib e nuovo intermedio di sintesi. |
| EP3337485B1 (en)* | 2015-08-19 | 2021-03-17 | Sun Pharmaceutical Industries Ltd | Crystalline forms of ibrutinib |
| US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
| WO2017040617A1 (en) | 2015-08-31 | 2017-03-09 | Pharmacyclics Llc | Btk inhibitor combinations for treating multiple myeloma |
| JP6802263B2 (ja) | 2015-09-02 | 2020-12-16 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| CN118063537A (zh) | 2015-09-08 | 2024-05-24 | 莫纳什大学 | 定向淋巴的前药 |
| WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| CA2904270A1 (en)* | 2015-09-11 | 2017-03-11 | Pharmascience Inc. | Protein kinase inhibitors |
| WO2017044720A1 (en) | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CN105753863B (zh)* | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
| MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
| CN108431007B (zh) | 2015-09-16 | 2022-06-07 | 洛克索肿瘤学股份有限公司 | 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物 |
| WO2017059224A2 (en) | 2015-10-01 | 2017-04-06 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
| CN106608877B (zh)* | 2015-10-21 | 2018-11-13 | 新发药业有限公司 | 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法 |
| SI3364958T1 (sl) | 2015-10-23 | 2023-05-31 | Navitor Pharmaceuticals, Inc. | Modulatorji interakcije sestrina in gator2 ter njihova uporaba |
| TWI642671B (zh)* | 2015-10-28 | 2018-12-01 | 台灣神隆股份有限公司 | 依魯替尼之製備方法及其中間體 |
| HUE064244T2 (hu)* | 2015-11-17 | 2024-02-28 | Merck Patent Gmbh | Módszerek szklerózis multiplex kezelésére BTK gátló aktivitású pirimidin- és piridin-származékokkal |
| CN105294696A (zh)* | 2015-11-19 | 2016-02-03 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
| EP4012415A3 (en) | 2015-12-04 | 2022-12-07 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
| CN108367006B (zh) | 2015-12-04 | 2021-12-31 | 博尔托拉制药公司 | 用于治疗血液癌症的赛度替尼 |
| JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| WO2017106352A1 (en) | 2015-12-14 | 2017-06-22 | Raze Therapeutics, Inc. | Caffeine inhibitors of mthfd2 and uses thereof |
| CN108368086B (zh) | 2015-12-16 | 2021-01-08 | 勃林格殷格翰国际有限公司 | 可用于治疗自身免疫疾病的二吡唑基衍生物 |
| MY202026A (en) | 2015-12-16 | 2024-03-29 | Loxo Oncology Inc | Compounds useful as kinase inhibitors |
| EP3402789B1 (en) | 2016-01-13 | 2020-03-18 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
| DK3402503T3 (da) | 2016-01-13 | 2020-12-21 | Acerta Pharma Bv | Terapeutiske kombinationer af et antifolat og en btk-hæmmer |
| JP7109365B2 (ja) | 2016-01-19 | 2022-07-29 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｂｔｋ阻害剤を含む製剤／組成物 |
| CN108472258B (zh) | 2016-01-19 | 2024-05-24 | 詹森药业有限公司 | 包含btk抑制剂的配制品/组合物 |
| US10793566B2 (en) | 2016-01-21 | 2020-10-06 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| KR102699906B1 (ko)* | 2016-01-21 | 2024-08-29 | 즈보 바이오폴라 창쉥 파마수티컬 컴퍼니 리미티드 | 브루톤 티로신 키나제 억제제 |
| CN105732638B (zh)* | 2016-01-22 | 2018-01-30 | 成都倍特药业有限公司 | 一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法 |
| CN106995446B (zh)* | 2016-01-22 | 2021-07-02 | 山东新时代药业有限公司 | 布鲁顿酪氨酸激酶抑制剂制备方法 |
| US10626117B2 (en) | 2016-02-01 | 2020-04-21 | Natco Pharma Limited | Process for the preparation of Ibrutinib |
| WO2017134685A2 (en)* | 2016-02-02 | 2017-08-10 | Sun Pharma Advanced Research Company Limited | Novel hydrazino compounds as btk inhibitors |
| WO2017134588A1 (en) | 2016-02-04 | 2017-08-10 | Shilpa Medicare Limited | Process for the preparation of ibrutinib |
| CN108602834B (zh)* | 2016-02-05 | 2021-01-08 | 北京盛诺基医药科技股份有限公司 | 一种布鲁顿酪氨酸激酶抑制剂 |
| GB2558514A (en)* | 2016-02-09 | 2018-07-18 | Azad Pharmaceutical Ingredients Ag | Process for the synthesis of stable amorphous ibrutinib |
| US10398655B2 (en) | 2016-02-18 | 2019-09-03 | Privo Technologies, Inc. | Two-stage microparticle-based therapeutic delivery system and method |
| CN105646498A (zh)* | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型f及制备方法 |
| CN105646499A (zh)* | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型g及制备方法 |
| US11014882B2 (en)* | 2016-03-09 | 2021-05-25 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| DK3426243T3 (da) | 2016-03-09 | 2021-07-19 | Raze Therapeutics Inc | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf |
| KR102416971B1 (ko) | 2016-03-11 | 2022-07-04 | 엔젤 파마슈티칼 컴퍼니, 리미티드 | 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법 |
| WO2017163257A1 (en)* | 2016-03-21 | 2017-09-28 | Ind-Swift Laboratories Limited | Process for preparing pure lh-pyrazolo[3,4-d] pyrimidine derivative |
| PL3436447T3 (pl) | 2016-03-31 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Kompleksy triazolonu izochinolinylowego |
| CZ2016196A3 (cs) | 2016-04-06 | 2017-10-18 | Zentiva, K.S. | Pevné formy Ibrutinibu |
| CN109153722A (zh) | 2016-04-08 | 2019-01-04 | X4 制药有限公司 | 用于治疗癌症的方法 |
| MX387394B (es) | 2016-04-15 | 2025-03-18 | Cancer Research Tech Ltd | Compuestos heterociclicos como inhibidores de la cinasa ret. |
| HRP20221051T8 (hr) | 2016-04-15 | 2023-07-21 | Cancer Research Technology Limited | Heterociklički spojevi kao inhibitori ret kinaze |
| WO2017184774A1 (en) | 2016-04-19 | 2017-10-26 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia |
| WO2017189999A1 (en)* | 2016-04-29 | 2017-11-02 | Dana-Farber Cancer Institute, Inc. | Hck as a therapeutic target in myd88 mutated diseases |
| CZ2016276A3 (cs) | 2016-05-11 | 2017-11-22 | Zentiva, K.S. | Pevné formy volné báze ibrutinibu |
| RS65474B1 (sr) | 2016-05-20 | 2024-05-31 | Biohaven Therapeutics Ltd | Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera |
| CN105859728B (zh)* | 2016-05-26 | 2018-06-08 | 江苏中邦制药有限公司 | 一种依鲁替尼的制备方法 |
| AU2017268839A1 (en) | 2016-05-27 | 2018-11-29 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders |
| EP3472162B1 (en) | 2016-06-16 | 2021-11-17 | F. Hoffmann-La Roche AG | Heteroaryl estrogen receptor modulators and uses thereof |
| EP3472159A1 (en) | 2016-06-16 | 2019-04-24 | F. Hoffmann-La Roche AG | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| EP3472168B1 (en)* | 2016-06-20 | 2024-01-10 | Novartis AG | Crystalline forms of triazolopyrimidine compound |
| JP7084624B2 (ja) | 2016-06-21 | 2022-06-15 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| CN116554168B (zh) | 2016-06-21 | 2025-09-23 | X4制药有限公司 | Cxcr4抑制剂及其用途 |
| US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| CN106117214A (zh)* | 2016-06-29 | 2016-11-16 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
| WO2018000250A1 (zh)* | 2016-06-29 | 2018-01-04 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
| KR102391693B1 (ko) | 2016-06-29 | 2022-04-29 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제 |
| AU2017287762C1 (en) | 2016-06-30 | 2020-04-23 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
| WO2018002958A1 (en) | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| EP3481831B1 (en)* | 2016-07-07 | 2023-09-06 | Daewoong Pharmaceutical Co., Ltd. | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same |
| CN107641123A (zh)* | 2016-07-20 | 2018-01-30 | 南京亿华药业有限公司 | 一种依鲁替尼及其关键中间体的制备新方法 |
| EP3487852A1 (en) | 2016-07-21 | 2019-05-29 | Biogen MA Inc. | Succinate forms and compositions of bruton's tyrosine kinase inhibitors |
| KR20250052473A (ko) | 2016-08-16 | 2025-04-18 | 베이진 스위찰랜드 게엠베하 | (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로[1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도 |
| CN109851620B (zh)* | 2016-08-17 | 2020-08-07 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制酪氨酸激酶活性的稠合双环类化合物 |
| HUE065528T2 (hu) | 2016-08-19 | 2024-06-28 | Beigene Switzerland Gmbh | Zanubrutinib kombinációja anti-CD20 vagy anti-PD-1 antitesttel rák kezelésében történõ alkalmazásra |
| IL292938A (en) | 2016-09-19 | 2022-07-01 | Mei Pharma Inc | Combination therapy |
| EP3523280A1 (en) | 2016-10-06 | 2019-08-14 | Janssen Pharmaceutica NV | Processes and intermediates for preparing a btk inhibitor |
| US10323036B2 (en) | 2016-10-14 | 2019-06-18 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| KR20190068544A (ko) | 2016-10-17 | 2019-06-18 | 다이이찌 산쿄 가부시키가이샤 | Mdm2 저해제와 dna 메틸트랜스페라아제 저해제의 병용 치료법 |
| AU2017345736B2 (en) | 2016-10-21 | 2022-04-07 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| WO2018078123A1 (en) | 2016-10-28 | 2018-05-03 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| AU2017355544A1 (en) | 2016-11-03 | 2019-05-16 | Juno Therapeutics, Inc. | Combination therapy of a T cell therapy and a BTK inhibitor |
| WO2018089499A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF |
| CA3043376A1 (en)* | 2016-11-15 | 2018-05-24 | Hangzhou Hertz Pharmaceutical Co., Ltd. | L-h-pyrazolo[3,4-d]pyrimidinyl derivatives and pharmaceutical compositions thereof useful as selective bruton's tyrosine kinase inhibitor |
| CN108101905A (zh)* | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| US10183024B2 (en) | 2016-12-02 | 2019-01-22 | Apotex Inc. | Crystalline forms of ibrutinib |
| US11590167B2 (en) | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
| US11091451B2 (en) | 2016-12-05 | 2021-08-17 | Raze Therapeutics, Inc. | SHMT inhibitors and uses thereof |
| CA3046578A1 (en)* | 2016-12-21 | 2018-06-28 | Acerta Pharma B.V. | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
| JP2020502238A (ja) | 2016-12-23 | 2020-01-23 | バイスクルアールディー・リミテッド | 新規連結構造を有するペプチド誘導体 |
| EP3565638B8 (en) | 2017-01-06 | 2024-04-10 | BicycleRD Limited | Bicycle conjugate for treating cancer |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| WO2018151849A1 (en) | 2017-02-17 | 2018-08-23 | Privo Technologies, Inc. | Particle-based multi-layer therapeutic delivery device and method |
| JP2020508326A (ja) | 2017-02-24 | 2020-03-19 | ギリアド サイエンシズ， インコーポレイテッド | ブルトン型チロシンキナーゼの阻害剤 |
| TWI754011B (zh) | 2017-02-24 | 2022-02-01 | 美商基利科學股份有限公司 | 布魯頓氏酪胺酸激酶之抑制劑 |
| JP7160824B2 (ja) | 2017-03-08 | 2022-10-25 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| CN108570036A (zh)* | 2017-03-09 | 2018-09-25 | 北京赛林泰医药技术有限公司 | 一种btk抑制剂的多晶型物及其制备方法 |
| GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
| EP3375778A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
| EP3375784A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aza-dihydro-acridone derivatives |
| JP2020514367A (ja)* | 2017-03-14 | 2020-05-21 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 細胞死の誘導のためのｂａｘ活性化の小分子敏感化 |
| EA201992147A1 (ru)* | 2017-03-22 | 2020-02-20 | Сужоу Байджибугонг Фрамасьютикал Текнолоджи Ко.Лтд | Ингибиторы тирозинкиназы брутона |
| WO2018191146A1 (en) | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| WO2018191815A1 (en) | 2017-04-20 | 2018-10-25 | Apotex Inc. | Processes for the preparation of acalabrutinib and intermediates thereof |
| CN107043366B (zh)* | 2017-04-25 | 2020-05-26 | 中国药科大学 | 4-氨基嘧啶类化合物、其制备方法及医药用途 |
| CA3061611A1 (en) | 2017-04-26 | 2018-11-01 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
| WO2018197893A1 (en) | 2017-04-27 | 2018-11-01 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| US10478403B1 (en) | 2017-05-03 | 2019-11-19 | Privo Technologies, Inc. | Intraoperative topically-applied non-implantable rapid release patch |
| JP7379164B2 (ja) | 2017-06-02 | 2023-11-14 | ジュノー セラピューティクス インコーポレイテッド | 細胞療法に関連する毒性に関する製造物品および方法 |
| MX2019014268A (es) | 2017-06-02 | 2020-08-03 | Juno Therapeutics Inc | Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva. |
| CN109111446B (zh) | 2017-06-22 | 2021-11-30 | 上海度德医药科技有限公司 | 一种具有药物活性的杂芳基化合物 |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| KR102757960B1 (ko) | 2017-06-26 | 2025-01-22 | 베이진 엘티디 | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 |
| MX2019015155A (es) | 2017-06-29 | 2020-08-03 | Juno Therapeutics Inc | Modelo de raton para valorar toxicidades asociadas con inmunoterapias. |
| WO2019013562A1 (ko) | 2017-07-12 | 2019-01-17 | 주식회사 대웅제약 | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
| KR102384924B1 (ko)* | 2017-07-12 | 2022-04-08 | 주식회사 대웅제약 | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
| DK3658557T3 (da) | 2017-07-28 | 2024-07-29 | Takeda Pharmaceuticals Co | Tyk2-inhibitorer og anvendelser deraf |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| WO2019034868A1 (en) | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF |
| US20200291096A1 (en) | 2017-08-14 | 2020-09-17 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| WO2019046491A1 (en) | 2017-08-29 | 2019-03-07 | Ariya Therapeutics, Inc. | LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM |
| US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| WO2019046832A1 (en) | 2017-09-01 | 2019-03-07 | Juno Therapeutics, Inc. | GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| EA037031B1 (ru)* | 2017-10-06 | 2021-01-28 | Асерта Фарма Б.В. | Имидазопиразиновые ингибиторы тирозинкиназы брутона |
| KR102613433B1 (ko)* | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
| TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
| WO2019126378A1 (en) | 2017-12-19 | 2019-06-27 | Ariya Therapeutics, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019127008A1 (zh)* | 2017-12-26 | 2019-07-04 | 清华大学 | 一种靶向降解btk的化合物及其应用 |
| CN108220261B (zh)* | 2017-12-29 | 2021-05-14 | 安徽联创生物医药股份有限公司 | 酮还原酶、核酸、重组表达载体、重组表达菌株及应用 |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CA3089537A1 (en) | 2018-01-20 | 2019-07-25 | Natco Pharma Limited | Pharmaceutical compositions comprising ibrutinib |
| US10988477B2 (en) | 2018-01-29 | 2021-04-27 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
| US10793563B2 (en) | 2018-01-29 | 2020-10-06 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
| MX2020008791A (es) | 2018-02-23 | 2021-01-08 | Bicycletx Ltd | Ligandos de peptidos biciclicos multimericos. |
| CA3091202A1 (en) | 2018-02-27 | 2019-09-06 | Artax Biopharma Inc. | Chromene derivatives as inhibitors of tcr-nck interaction |
| EP3773591A4 (en) | 2018-04-05 | 2021-12-22 | Sumitomo Dainippon Pharma Oncology, Inc. | AXL KINASE INHIBITORS AND THEIR USE |
| US20210113562A1 (en) | 2018-04-13 | 2021-04-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
| US10815225B2 (en) | 2018-04-24 | 2020-10-27 | Merck Patent Gmbh | Antiproliferation compounds and uses thereof |
| EP3784669B1 (en) | 2018-04-24 | 2023-10-25 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
| KR102106821B1 (ko) | 2018-04-27 | 2020-05-06 | 재단법인대구경북과학기술원 | 이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
| EP3789040A4 (en) | 2018-04-27 | 2022-03-09 | ONO Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT |
| SG11202010642TA (en) | 2018-05-03 | 2020-11-27 | Juno Therapeutics Inc | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| WO2019213606A2 (en) | 2018-05-04 | 2019-11-07 | Portola Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
| EP3575300A1 (en) | 2018-05-31 | 2019-12-04 | Apotex Inc. | Novel crystalline forms of ibrutinib |
| IL259810A (en) | 2018-06-04 | 2018-07-31 | Yeda Res & Dev | Mitogen-activated protein kinase kinase 7 inhibitors |
| RU2711106C2 (ru)* | 2018-06-06 | 2020-01-15 | Общество с ограниченной ответственностью "АКСЕЛЬФАРМ" | Кристаллическая μ-модификация 1-[(3R)-3-[4-амино-3-(4-фенокси-фенил)-1Н-пиразоло[3,4-d]пиримидин-1-ил]-1-пиперидил]-2-пропенил-1-она, способ её получения и фармацевтическая композиция на её основе |
| CN118512397A (zh) | 2018-06-15 | 2024-08-20 | 詹森药业有限公司 | 包含依鲁替尼的配制品/组合物 |
| AU2019286524B2 (en) | 2018-06-15 | 2025-03-06 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| AU2019295632B2 (en) | 2018-06-25 | 2025-03-06 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| AU2019310590A1 (en) | 2018-07-26 | 2021-01-14 | Sumitomo Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| US12109193B2 (en) | 2018-07-31 | 2024-10-08 | Loxo Oncology Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
| KR102328682B1 (ko) | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| WO2020045941A1 (ko) | 2018-08-27 | 2020-03-05 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2020043321A1 (en) | 2018-08-31 | 2020-03-05 | Stichting Katholieke Universiteit | Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof |
| CN113164419A (zh) | 2018-09-07 | 2021-07-23 | 皮克医疗公司 | Eif4e抑制剂和其用途 |
| CN110964016B (zh)* | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
| WO2020081508A1 (en) | 2018-10-15 | 2020-04-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| JP2022512779A (ja) | 2018-10-23 | 2022-02-07 | バイスクルテクス・リミテッド | 二環式ペプチドリガンドおよびその使用 |
| AU2019364542B2 (en) | 2018-10-24 | 2025-08-28 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| CN111170986A (zh) | 2018-11-13 | 2020-05-19 | 北京睿熙生物科技有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
| CN109293630A (zh)* | 2018-11-15 | 2019-02-01 | 山东大学 | 含取代吡唑类化合物及其制备方法与应用 |
| CN109369654A (zh)* | 2018-11-20 | 2019-02-22 | 山东大学 | 1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用 |
| JP7530360B2 (ja) | 2018-11-30 | 2024-08-07 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| FI3886894T3 (fi) | 2018-11-30 | 2024-05-24 | Juno Therapeutics Inc | Menetelmiä annosteluun ja b-solumaligniteettien hoitoon adoptiivisessa soluterapiassa |
| BR112021010484A2 (pt) | 2018-11-30 | 2021-08-24 | Kymera Therapeutics, Inc. | Degradadores de irak e usos dos mesmos |
| EP3886875B1 (en) | 2018-11-30 | 2024-05-08 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
| EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
| AU2019407426A1 (en) | 2018-12-21 | 2021-07-22 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| EP3669867A1 (en) | 2018-12-21 | 2020-06-24 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| US10688050B1 (en) | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| WO2020140098A1 (en) | 2018-12-28 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| AU2020206884A1 (en) | 2019-01-09 | 2021-08-05 | Beth Israel Deaconess Medical Center, Inc. | Modulators of Pin1 activity and uses thereof |
| CN111454268B (zh)* | 2019-01-18 | 2023-09-08 | 明慧医药（上海）有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
| JP7699052B2 (ja) | 2019-01-23 | 2025-06-26 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| CN113412262A (zh) | 2019-02-12 | 2021-09-17 | 大日本住友制药肿瘤公司 | 包含杂环蛋白激酶抑制剂的制剂 |
| WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| WO2020170270A1 (en)* | 2019-02-19 | 2020-08-27 | Msn Laboratories Private Limited, R&D Center | Novel crystalline polymorphs of 1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and process for preparation thereof |
| MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
| AU2020253990A1 (en) | 2019-04-02 | 2021-10-28 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| BR112021019748A2 (pt) | 2019-04-05 | 2021-12-07 | Kymera Therapeutics Inc | Degradadores de stat e usos dos mesmos |
| KR20220011668A (ko) | 2019-05-21 | 2022-01-28 | 얀센 파마슈티카 엔.브이. | Btk 억제제 제조를 위한 방법 및 중간체 |
| CN113906011B (zh) | 2019-05-21 | 2025-05-13 | 詹森药业有限公司 | 用于制备btk抑制剂的方法和中间体 |
| US10937541B2 (en) | 2019-05-28 | 2021-03-02 | PAIGE.AI, Inc. | Systems and methods for processing images to prepare slides for processed images for digital pathology |
| MX2021014441A (es) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
| WO2020249001A1 (zh) | 2019-06-10 | 2020-12-17 | 百济神州瑞士有限责任公司 | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
| CN115038688A (zh) | 2019-09-11 | 2022-09-09 | 文森雷生物科学股份有限公司 | Usp30抑制剂及其用途 |
| PH12022550605A1 (en) | 2019-09-13 | 2023-09-25 | Nimbus Saturn Inc | Hpk1 antagonists and uses thereof |
| CA3154257A1 (en) | 2019-10-14 | 2021-04-22 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| TWI870497B (zh) | 2019-11-01 | 2025-01-21 | 美商奈維特製藥公司 | 使用mtorc1調節劑的治療方法 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| US11819476B2 (en) | 2019-12-05 | 2023-11-21 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| US20230053787A1 (en) | 2019-12-06 | 2023-02-23 | Juno Therapeutics, Inc. | Methods related to toxicity and response associated with cell therapy for treating b cell malignancies |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADATION AGENTS AND THEIR USES |
| BR112022011651A2 (pt) | 2019-12-17 | 2022-08-23 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| CN115297931A (zh) | 2019-12-23 | 2022-11-04 | 凯麦拉医疗公司 | Smarca降解剂和其用途 |
| TWI883107B (zh) | 2020-01-20 | 2025-05-11 | 美商普林斯匹亞生物製藥公司 | 用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑 |
| TW202140484A (zh) | 2020-01-22 | 2021-11-01 | 美商普林斯匹亞生物製藥公司 | ２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）－１Ｈ－吡唑并［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈之晶形 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4100017A4 (en) | 2020-02-05 | 2024-04-10 | PureTech LYT, Inc. | Lipid prodrugs of neurosteroids |
| CN113336760B (zh)* | 2020-02-18 | 2022-11-04 | 深圳市塔吉瑞生物医药有限公司 | 取代的酰胺衍生物及其组合物及用途 |
| MX2022010391A (es) | 2020-02-26 | 2022-09-05 | Daewoong Pharmaceutical Co Ltd | Metodo de preparacion de derivados de amina heterociclica. |
| EP4114529A1 (en) | 2020-03-03 | 2023-01-11 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| US20240424110A1 (en) | 2020-03-19 | 2024-12-26 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| CN114057724B (zh)* | 2020-07-29 | 2025-01-03 | 鲁南制药集团股份有限公司 | 一种btk抑制剂 |
| JP2023538906A (ja) | 2020-08-17 | 2023-09-12 | バイシクルティーエクス・リミテッド | ネクチン－４に特異的な二環コンジュゲート及びその使用 |
| EP4203923B1 (en) | 2020-08-28 | 2025-10-01 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| US20240024325A1 (en)* | 2020-08-28 | 2024-01-25 | Emory University | Methods of Managing Cocaine or Other Drug Addictions |
| CN114105990A (zh)* | 2020-08-31 | 2022-03-01 | 北京四环制药有限公司 | 一种伊布替尼的合成方法 |
| CN114105991A (zh)* | 2020-08-31 | 2022-03-01 | 北京四环制药有限公司 | 一种伊布替尼中间体的制备方法 |
| CN116601131A (zh) | 2020-10-23 | 2023-08-15 | 林伯士克洛索有限公司 | Ctps1抑制剂及其用途 |
| CN114478548A (zh)* | 2020-10-23 | 2022-05-13 | 上海润石医药科技有限公司 | 一种布鲁顿酪氨酸激酶抑制剂的用途 |
| IL303376A (en) | 2020-12-02 | 2023-08-01 | Ikena Oncology Inc | Tead inhibitors and uses thereof |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| AU2021398051A1 (en) | 2020-12-10 | 2023-07-27 | Principia Biopharma Inc. | Crystal form of tolebrutinib, preparation method therefor and use thereof |
| CN112574216B (zh)* | 2020-12-16 | 2022-03-08 | 天津济坤医药科技有限公司 | 一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用 |
| AU2021413371A1 (en) | 2020-12-30 | 2023-07-13 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US20240092785A1 (en) | 2021-01-21 | 2024-03-21 | Synthon B.V. | Process for making ibrutinib |
| AU2022215844A1 (en) | 2021-02-02 | 2023-09-14 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| CA3206501A1 (en) | 2021-02-02 | 2022-08-11 | Shaun Abbott | Gpr84 antagonists and uses thereof |
| US12252488B2 (en) | 2021-02-12 | 2025-03-18 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| MX2023009527A (es) | 2021-02-15 | 2023-08-24 | Kymera Therapeutics Inc | Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos. |
| AU2022220869A1 (en) | 2021-02-15 | 2023-08-24 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| JP2024509192A (ja) | 2021-03-05 | 2024-02-29 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
| JP2024513011A (ja) | 2021-03-29 | 2024-03-21 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
| CN115160319B (zh)* | 2021-04-01 | 2023-12-26 | 西安新通药物研究股份有限公司 | 含1,3-苯并二氧戊环结构的化合物及其制备方法与用途 |
| IL307479A (en) | 2021-04-09 | 2023-12-01 | Nimbus Clio Inc | Cbl-b modulators and uses thereof |
| EP4323066A1 (en) | 2021-04-16 | 2024-02-21 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| PH12023500023A1 (en) | 2021-05-07 | 2024-03-11 | Kymera Therapeutics Inc | Cdk2 degraders and uses thereof |
| AU2022286943A1 (en)* | 2021-06-01 | 2023-12-07 | Privo Technologies, Inc. | Enhanced two-stage microparticle-based localized therapeutic delivery system |
| MA63498A1 (fr) | 2021-06-10 | 2024-07-31 | Hikma Pharmaceuticals Usa Inc. | Formes posologiques orales d'ibrutinib |
| US11433072B1 (en) | 2021-06-10 | 2022-09-06 | Hikma Pharmaceuticals USA, Inc. | Oral dosage forms of ibrutinib |
| CN113583001A (zh)* | 2021-07-13 | 2021-11-02 | 江苏君若药业有限公司 | 依鲁替尼的制备 |
| WO2023014817A1 (en) | 2021-08-03 | 2023-02-09 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor |
| CN115702898B (zh)* | 2021-08-04 | 2024-02-09 | 成都倍特药业股份有限公司 | 一种btk抑制剂固体制剂及其制备方法 |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| JP2024534127A (ja) | 2021-08-25 | 2024-09-18 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| CN113845521B (zh)* | 2021-08-31 | 2024-06-18 | 中原工学院 | 水相中光催化一锅法合成咪唑并含氮杂环肼类衍生物的方法 |
| WO2023071973A1 (en)* | 2021-10-26 | 2023-05-04 | Shenzhen Targetrx, Inc. | Fused bicyclic compound for inhibiting activity of tyrosine kinase |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその合成 |
| EP4444276A1 (en) | 2021-12-10 | 2024-10-16 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| TW202339738A (zh) | 2022-01-31 | 2023-10-16 | 美商凱麥拉醫療公司 | Irak降解物及其用途 |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| CN114605418B (zh)* | 2022-03-15 | 2023-09-05 | 广东医科大学附属医院 | 一类具有抗肿瘤活性的依鲁替尼丙烯酰胺类衍生物及其合成方法与应用 |
| WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| JP2025519119A (ja) | 2022-05-25 | 2025-06-24 | イケナ オンコロジー， インコーポレイテッド | Ｍｅｋ阻害剤及びその使用 |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| WO2023242384A1 (en) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Crystalline form of ibrutinib |
| WO2023249980A1 (en)* | 2022-06-22 | 2023-12-28 | Genzyme Corporation | Methods of making modified btk inhibitors |
| CN120051456A (zh) | 2022-08-02 | 2025-05-27 | 里米诺生物科学有限公司 | 取代的吡啶酮gpr84拮抗剂及其用途 |
| AU2023317740A1 (en) | 2022-08-02 | 2025-03-13 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
| TW202415650A (zh) | 2022-08-02 | 2024-04-16 | 英商利米那生物科技有限公司 | 芳基-三唑基及相關gpr84拮抗劑及其用途 |
| CN115417827B (zh)* | 2022-09-30 | 2023-05-26 | 中国药科大学 | 6-氨基-1,3,5-三嗪类化合物及其合成方法和应用 |
| CN120302975A (zh) | 2022-10-31 | 2025-07-11 | 住友制药美国公司 | 治疗骨髓增生性肿瘤的pim1抑制剂 |
| US20240208961A1 (en) | 2022-11-22 | 2024-06-27 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| WO2024235166A1 (zh)* | 2023-05-12 | 2024-11-21 | 武汉人福创新药物研发中心有限公司 | 含有btk抑制剂的组合物及其用途 |
| WO2024240025A1 (zh)* | 2023-05-22 | 2024-11-28 | 无锡瓴方生物医药科技有限公司 | 一种联合用药物组合物及其应用 |
| US20250059164A1 (en) | 2023-06-23 | 2025-02-20 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2025062372A1 (en) | 2023-09-21 | 2025-03-27 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |